Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

PHA 543613

Copy Product Info
😃Good
Catalog No. T23145Cas No. 478149-53-0

PHA 543613 is a specific agonist of α7 nAChR (Ki = 8.8 nM) and can be used in studies about the cognitive deficits of Alzheimer's disease and schizophrenia.

PHA 543613

PHA 543613

Copy Product Info
😃Good
Purity: 99.96%
Catalog No. T23145Cas No. 478149-53-0
PHA 543613 is a specific agonist of α7 nAChR (Ki = 8.8 nM) and can be used in studies about the cognitive deficits of Alzheimer's disease and schizophrenia.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$46In StockIn Stock
5 mg$109In StockIn Stock
10 mg$178In StockIn Stock
25 mg$397In StockIn Stock
50 mg$678In StockIn Stock
100 mg$995-In Stock
500 mg$2,160-In Stock
1 mL x 10 mM (in DMSO)$107In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.96%
Appearance:Solid
Color:Yellow
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
PHA 543613 is a specific agonist of α7 nAChR (Ki = 8.8 nM) and can be used in studies about the cognitive deficits of Alzheimer's disease and schizophrenia.
Targets&IC50
α7 nAChR:8.8 nM (Ki)
In vivo
In rats, PHA-543613 (0.3 mg/kg) reverses Scopolamine-induced short-term memory deficits[2]. Intraperitoneal injection of PHA-543613 (4 and 12 mg/kg) increases p-Akt and decreases p-GSK-3 and CC3 expressions in the ipsilateral hemisphere. PHA-543613 reduces neuronal cell death in the perihematomal area[3].
Chemical Properties
Molecular Weight271.31
FormulaC15H17N3O2
Cas No.478149-53-0
SmilesO=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1
Relative Density.1.32 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 225 mg/mL (829.31 mM), Sonication is recommended.
H2O: < 30.78 mg/mL, Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM3.6858 mL18.4291 mL36.8582 mL184.2910 mL
5 mM0.7372 mL3.6858 mL7.3716 mL36.8582 mL
10 mM0.3686 mL1.8429 mL3.6858 mL18.4291 mL
20 mM0.1843 mL0.9215 mL1.8429 mL9.2146 mL
50 mM0.0737 mL0.3686 mL0.7372 mL3.6858 mL
100 mM0.0369 mL0.1843 mL0.3686 mL1.8429 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy PHA 543613 | purchase PHA 543613 | PHA 543613 cost | order PHA 543613 | PHA 543613 chemical structure | PHA 543613 in vivo | PHA 543613 formula | PHA 543613 molecular weight